Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.43, $0.09 better than the analyst estimate of $2.34. Revenue for the quarter came in at $1 billion versus the consensus estimate of $987.43 million.

GUIDANCE:

Charles River Laboratories sees FY2025 EPS of $10.10-$10.30, versus the consensus of $10.19.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.